Compare DexCom, Inc. (DXCM) vs Sherwin-Williams Company (The) Common Stock (SHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Sherwin-Williams Company (The) Common Stock — how do they compare? DexCom, Inc. trades at $84.41 (market cap $32.09B), while Sherwin-Williams Company (The) Common Stock trades at $327.77 (market cap $78.68B). The key difference: Sherwin-Williams Company (The) Common Stock is far larger — about 2.5× DexCom, Inc.'s market cap, and Sherwin-Williams Company (The) Common Stock pays a 0.99% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | SHW | |
|---|---|---|
Market Cap | $32.09B | $78.68B |
Volume | 3,819,730 | 1,245,324 |
Sector | Health | Basic Materials |
52-Week High | $92.34 | $372.60 |
52-Week Low | $54.84 | $293.00 |
Typical Hold Time | 62 Days | — |
Enterprise Value | $31.54B | $92.60B |
Dividend Yield | — | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $83.47, down 2.85% on the day, amid a generally bullish technical and fundamental backdrop. The stock shows strong revenue growth, with 2025 revenue reaching $4.66 billion and net income of $836.3 million, and has consistently beaten earnings expectations. Analyst consensus is strongly positive with a price target of $96.14, and recent news highlights expansion opportunities in the Type 2 diabetes CGM market.
The outlook for DXCM is positive, driven by solid financial performance and market expansion potential. Key opportunities include growing adoption of its CGM systems, while risks involve competitive pressures and reimbursement challenges. The stock presents a compelling case for growth-oriented investors, supported by strong analyst backing and institutional interest.
Sherwin-Williams (SHW) trades at $324.10, up 1.21% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows neutral technical signals but maintains robust fundamentals with 65.12% ROE and expanding manufacturing capacity. Recent facility expansions in Statesville enhance production capabilities, positioning the company for continued market share gains.
Outlook remains positive with analyst consensus at Buy (57.9%) and $383.64 price target, though high valuation multiples (P/E 29.9) and competitive pressures present risks. Earnings growth and strategic investments support upside potential, while margin compression and economic sensitivity warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Sherwin-Williams Company (The) Common Stock
The Sherwin-Williams Company manufactures, develops, and distributes paints, coatings, and related products through three segments: Paint Stores Group, operating more than 4,900 company-owned stores selling Sherwin-Williams-branded products; Consumer Brands Group, selling brands such as Valspar, Dutch Boy, Krylon, and Minwax through mass merchandisers and home centers; and Performance Coatings Group, supplying industrial, construction, and transportation coatings in more than 120 countries.
Read more on SHW →
